ProVent Trial for Newly Diagnosed Prostate Cancer - Benjamin Lowentritt


Benjamin Lowentritt and Alicia Morgans discuss the ProVent trial, the use of sipuleucel-T in newly diagnosed prostate cancer patients on active surveillance.  They discuss inclusion criteria, trial design and primary outcome measures which include assessing the efficacy of sipuleucel-T in reducing reclassification to a higher Gleason grade in patients on active surveillance. 

Biographies:

Alicia Morgans, MD, MPH

Benjamin H. Lowentritt, MD, FACS, Director, Minimally Invasive Surgery and Robotics, Chesapeake Urology Associates, Director, Prostate Cancer Care Program, Chesapeake Urology Associates, and Past President, Baltimore City Medical Society
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe